ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
Provided By GlobeNewswire
Last update: Aug 13, 2025
U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review
PRECISE-AD Phase 1b Trial in Alzheimer’s Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date
Read more at globenewswire.com
